Saccharomyces cerevisiae Pathway Optimization

In most cases, yes. Projects can start from a customer-supplied S. cerevisiae background or from a strain selected during scoping. We review auxotrophies, selection markers, and any prior edits before designing constructs, so the final strategy matches the background your team intends to use downstream.

Both routes are available and the choice is made case by case during design. Replicating plasmids can support earlier screening rounds, while chromosomal integration is often considered when construct stability across cultivation steps matters. The selected configuration is documented in the project scope before construction begins.

Read-outs are agreed at scoping and can include quantification of pathway intermediates or target products in the cultivation format used for the project. We report measured values with the associated methods and conditions so your team can interpret them; conclusions about scale-up or commercial performance depend on your own process context.

Handoff typically includes a project report with construct maps, methods summaries, and result tables, together with strain and plasmid materials when those are included in scope. The exact inventory of materials and datasets is listed in the statement of work, so expectations are settled before work starts.

No. Pathway outcomes depend on the target biology, host background, and cultivation conditions, so we do not promise titers or yields. Instead, we define measurable project milestones and acceptance criteria with your team during scoping, and report what was observed under the agreed conditions.